The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The Europe generic injectables market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to continue its strong growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic injectables refer to alternative drugs that are equivalent to their branded counterparts in terms of the dosage, quality, strength, performance, and intended use. Generic injectables are beneficial in treating various life-threatening and chronic diseases, such as cancer, diabetes, rheumatoid arthritis, cardiovascular ailments, and respiratory infections. They aim to maximize patient compliance and reduce the frequency of administered dosage, thereby maintaining the effectiveness of the treatment.
The increasing prevalence of chronic diseases across Europe represents the key factor driving the market growth. In line with this, intravenous (IV) and intramuscular (IM) routes of drug administration are gaining widespread preference in the healthcare sector for fast drug delivery and for treating patients that are incapable of taking oral doses of medication. This is contributing to the market growth in the region significantly. Additionally, generic injectables are cost-effective as compared to branded drugs, which is acting as another growth-inducing factor. Apart from this, the increasing shortage of medicines and expiry of patents of branded items, are further creating a positive outlook for the market in Europe.
IMARC Group provides an analysis of the key trends in each sub-segment of the Europe generic injectables market, along with forecasts at the regional and country level from 2021-2026. Our report has categorized the market based on therapeutic area, container and distribution channel.
Breakup by Therapeutic Area:
Breakup by Container:
Breakup by Distribution Channel:
Breakup by Country:
The competitive landscape of the industry has also been examined along with the profiles of the key players.
|Base Year of the Analysis||2020|
|Segment Coverage||Therapeutic Area, Container, Distribution Channel, Country|
|Countries Covered||Germany, France, United Kingdom, Italy, Spain, Others|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at